Phase I Trial of Radiation With Concurrent and Consolidation Pemetrexed and Cisplatin in Patients With Unresectable Stage IIIA/B Non-Small-Cell Lung Cancer

Article ID	Journal	Published Year	Pages	File Type
8230461	International Journal of Radiation OncologyBiologyPhysics	2011	7 Pages	PDF

Abstract

Full systemic dose pemetrexed seems to be safe with full-dose cisplatin and thoracic radiation in Stage IIIA/B NSCLC. Pemetrexed is the first third-generation cytotoxic agent tolerable at full dose in this setting. A Phase II study evaluating Dose Level 4 is ongoing.

Keywords

Radiotherapy Non-small cell lung cancer Chemoradiotherapy Phase I trial Pemetrexed

Related Topics

Physical Sciences and Engineering Physics and Astronomy Radiation

Preview

Phase I Trial of Radiation With Concurrent and Consolidation Pemetrexed and Cisplatin in Patients With Unresectable Stage IIIA/B Non-Small-Cell Lung Cancer

Authors

Anthony M.D., C.M., Ph.D., Andrea M.D., C.M., Robert M.D., Scott M.D., Alex M.D., John M.D., Ph.D., Natasha M.D., Shannon R.T.T., Bernadette R.N., Lisa M.Sc., Shauna M.Sc., Neill M.D., Frances A. M.D.,